关于莱沃多巴与大脑疾病的相互作用 纳米级的氨基原蛋白
Talia Bergaglio1,2, Nico Kummer1, Shayon Bhattacharya3
1Transport at Nanoscale Interfaces Laboratory, Swiss Federal Laboratories for Materials Science and Technology, CH-8600 Dübendorf, Switzerland.
ACS omega
|April 21, 2025
概括
列沃多巴 (L-dopa) 降低了粉样蛋白聚合物的大小,这与帕金森病 (PD) 有关. 这一发现表明,L-dopa可能有助于逆转PD病理中的蛋白质聚合.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 生物物理学的生物物理.
背景情况:
- 大脑中α-synuclein (α-Syn) 和粉样β-1-42 (Aβ-42) 蛋白质的积累是帕金森病 (PD) 病理学的核心.
- 列沃多巴 (L-dopa) 是PD运动症状的主要治疗方法,但其对蛋白质聚合的影响尚未完全理解.
研究的目的:
- 研究L-多巴对α-Syn和Aβ-42蛋白纤维的形态的纳米效应.
- 为了探索L-dopa在逆转粉原蛋白聚合中的潜力.
主要方法:
- 原子力显微镜 (AFM) 用于无标签的蛋白质纤维状形态的纳米尺度成像.
- 用原子级分子动力学模拟来支持实验结果.
主要成果:
- L-dopa治疗显著减少了α-Syn和Aβ-42蛋白纤维的长度和直径.
- 对于Aβ-42,观察到纤维细胞大小的显著减少,特别是在生理缓冲区和人类脑脊液中.
结论:
- L-dopa 证明了在纳米尺度上拆解氨基原蛋白聚合物的能力.
- 这些发现表明,通过逆转蛋白质聚合,L-dopa可能在缓解PD病理方面发挥作用,为新的治疗策略提供了潜力.
相关概念视频
Amyloid Fibrils
9.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.0K
Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317


